74 results
8-K
EX-99.1
IVVD
Invivyd Inc
22 May 24
Invivyd Elects Two New Independent Members to its Board of Directors
7:06am
at McKinsey & Company advising clients on topics of strategy, growth, and market access in the life sciences industry and over 10 years leading
8-K
EX-99.2
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
IS RAPIDLY EXECUTING ON ITS COMMERCIAL STRATEGY Product Securing Full Commercial Availability Reimbursement Implementation & Access Deploy national … and doses that improve access and the not update except through the PEMGARDA Fact Sheet medical value associated with protection and treatment
8-K
EX-99.1
IVVD
Invivyd Inc
9 May 24
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:08pm
for purchase in the U.S. through a network of authorized specialty distributors. At the end of April, Invivyd’s market access and sales, as well
8-K
EX-99.2
11hugujw
4 Apr 24
Invivyd Provides PEMGARDATM Launch Update and Announces 2024 Net Product
5:25pm
8-K
EX-99.1
v1uuxrhj84pb01l0c
28 Mar 24
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
7:05am
8-K
EX-99.1
ohzkkysmo vz2k4q
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.3
km8ghpb hdl
22 Mar 24
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
8:58pm
8-K
EX-99.1
0yzw5yswbzwhtj3c51
9 Feb 24
Index to Consolidated Financial Statements
4:01pm
8-K
EX-99.1
va6264jqgymo9 j6
8 Jan 24
Other Events
7:12am
8-K
EX-10.1
x5jgsoz
22 Dec 23
Entry into a Material Definitive Agreement
4:53pm
8-K
EX-99.1
2os4r48
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm
8-K
EX-99.2
lw57lmfqjouhaznbdm9
9 Nov 23
Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:10pm